New drug combo aims to cut steroid use in painful rheumatic condition

NCT ID NCT07279688

Recruiting now Disease control Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether adding baricitinib (a JAK inhibitor pill) to standard steroid treatment can help people with polymyalgia rheumatica achieve disease control without needing long-term steroids. About 140 adults aged 50+ with active PMR will receive baricitinib (2 mg or 4 mg) or a placebo for 6 months, alongside tapering steroids. The main goal is to see if more patients can maintain low disease activity without steroids at 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Baricitinib (a JAK inhibitor drug taken as a tablet)
What this could lead to: If successful, this could offer a steroid-sparing treatment option for polymyalgia rheumatica, reducing long-term steroid side effects.
What could go wrong: This is a Phase 3 trial, but baricitinib carries risks of serious infections, heart problems, and cancer. The benefit over steroids is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

polymyalgia rheumatica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POLYMYALGIA RHEUMATICA (PMR)

Contacts and locations

Locations

APHP - Kremlin-Bicêtre
NOT_YET_RECRUITING

Le Kremlin-Bicêtre, 94270, France
Besançon-CIC
RECRUITING

Besançon, 25000, France
CARVAJAL ALEGRIA Guillermo
RECRUITING

Tours, France
CHU Reims
NOT_YET_RECRUITING

Reims, France
CHU de Bordeaux Pellegrin
NOT_YET_RECRUITING

Bordeaux, 33076, France
CHU de Nice
RECRUITING

Nice, 06000, France
CHU de Toulouse
NOT_YET_RECRUITING

Toulouse, 31059, France
DIREZ Guillaume
RECRUITING

Le Mans, France
Dr Alain SARAUX
RECRUITING

Brest, France
FAUTREL Bruno - AP-HP La Pitié-Salpétrière
NOT_YET_RECRUITING

Paris, France
FLIPO René-Marc
NOT_YET_RECRUITING

Lille, France
GOTTENBERG Jacques-Eric
RECRUITING

Strasbourg, France
LE HENAFF Catherine
RECRUITING

Morlaix, France
LEGRAND Jean-Louis
NOT_YET_RECRUITING

Arras, France
LESKE Charles
RECRUITING

Cholet, France
OTTAVIANI Sébastien - AP-HP Bichat
NOT_YET_RECRUITING

Paris, France
PRATI Clément
RECRUITING

Besançon, France
RAMON André
NOT_YET_RECRUITING

Dijon, France
RAT Anne-Christine
RECRUITING

Caen, France
TOURNADRE Anne
NOT_YET_RECRUITING

Clermont-Ferrand, France
VIDAL François
RECRUITING

Aix-en-Provence, France
WIRTH Théo
RECRUITING

Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.